Learn About Laura Greco and her Die, Cancer, Die! Campaign

Autologous hematopoietic cell transplantation, compared with CAR-T cell therapy, resulted in lower rates of relapse and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

The stem cell thrapy, Orca-T led to promising relapse-free and overall survival rates in patients with intermediate- to high-risk myelodysplastic syndrome.

Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’

The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens.

Brukinsa led to improved progression-free survival over Imbruvica in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follow-up from the phase 3 ALPINE study showed.